AMLo Biosciences Limited
Lead Participant:
AMLO BIOSCIENCES LIMITED
Abstract
Melanoma is a skin cancer with an increasing worldwide incidence. The risk of the primary tumour spreading is
estimated based on microscopic appearance and depth of the original tumour. Tumours classified as low risk are
followed up clinically over five years but approximately 10% of these low-risk (stage I) patients will develop
metastatic disease with an extremely poor prognosis. There is therefore an urgent unmet need to develop new
tests to accurately determine an individual’s risk of disease progression. We have identified two proteins (AMLo)
in the skin overlying the primary tumour which are lost in high-risk melanoma. We have validated this test in over
400 melanoma Stage I biopsies with known clinical outcomes and have shown that use of this test can accurately
predict melanomas which are genuinely low-risk and those which are high-risk and needing increased
surveillance and treatment. We intend to produce a diagnostic kit to measure AMLo in tumour tissue biopsies
suitable for large-scale manufacture fitting seamlessly into the existing procedures. The use of AMLo in clinical
practice has real potential to reduce costs to the NHS, provide reassurance and improving outcomes of patients.
estimated based on microscopic appearance and depth of the original tumour. Tumours classified as low risk are
followed up clinically over five years but approximately 10% of these low-risk (stage I) patients will develop
metastatic disease with an extremely poor prognosis. There is therefore an urgent unmet need to develop new
tests to accurately determine an individual’s risk of disease progression. We have identified two proteins (AMLo)
in the skin overlying the primary tumour which are lost in high-risk melanoma. We have validated this test in over
400 melanoma Stage I biopsies with known clinical outcomes and have shown that use of this test can accurately
predict melanomas which are genuinely low-risk and those which are high-risk and needing increased
surveillance and treatment. We intend to produce a diagnostic kit to measure AMLo in tumour tissue biopsies
suitable for large-scale manufacture fitting seamlessly into the existing procedures. The use of AMLo in clinical
practice has real potential to reduce costs to the NHS, provide reassurance and improving outcomes of patients.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
AMLO BIOSCIENCES LIMITED | £218,800 | £ 218,800 |
  | ||
Participant |
||
UNIVERSITY OF NEWCASTLE | ||
PRO-PANEM LIMITED | ||
INNOVATE UK |
People |
ORCID iD |
Ashleigh McConnell (Project Manager) |